triple antagonist glp-1 Transforming obesity: The advancement of multi-receptor drugs: Cell Beyond GLP-1: the next wave

It enrolled 17,604 adults aged 45 or older with a body mass index (BMI) of 27 kg/m2 or greater and preexisting CVD (prior MI, prior stroke or peripheral artery disease) without diabetes

Plaintiffs allege that pharmaceutical companies failed to provide adequate warnings about these risks on product labels and in marketing materials

With compounding pharmacies unable to broadly manufacture GLP-1s, it may spur demand for low-cost versions of semaglutide

Jason Wersland reveals how mastering your heart rate variability and internal chemistry can unlock a new level of longevity

Third , the market is shifting from access to accountability